Avid Bioservices Inc (CDMO)

[freethemice]

However, at the Chicago Symposium the late breaking Plenary just before Gerber's talk
was about the very same trial and abstract also withdrawn from the ESMO meeting!
At Chicago:
1:30 p.m. - 1:40 p.m.
LBPL1 A Randomized, Open-label, Phase 3, Superiority Study of Pemetrexed
(Pem)+Carboplatin (Cb)+Bevacizumab (B) Followed by Maintenance Pem+B
Versus Paclitaxel (Pac)+Cb+B Followed by Maintenance B in Patients (Pts) with
Stage IIIB or IV Non-squamous Non-small Cell Lung Cancer (Ns-Nsclc)
Jyoti Patel

1:40 p.m. - 1:50 p.m.
LBPL2 Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of
Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced
or Metastatic Non-Squamous Non-Small-Cell Lung Cancer (Top-line Results)
David Gerber

At Vienna:
LBA32 - A phase 3 superiority study of pemetrexed
(Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by
maintenance Pem+Bev versus paclitaxel (Pac)+Cb+Bev
followed by maintenance Bev in stage IIIB or IV nonsquamous
non-small cell lung cancer (NS-NSCLC): Overall
and age group results
Jyoti Patel, Chicago, IL, USA

LBA35 - Randomized, double-blind, placebo (P)-controlled
phase 2 trial of bavituximab (B) plus docetaxel (D) in patients
with previously treated locally advanced or metastatic nonsquamous
non-small-cell lung cancer
David Gerber, Dallas, TX, USA